NCT03249103 - Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

April 18, 2019

Study Completion Date

April 18, 2019

Conditions

Fibromyalgia

Interventions

DRUG

NYX-2925

NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).

DRUG

Placebo oral capsule

Matching placebo capsules.

Trial Locations (2)

Aptinyx Clinical Site, Cincinnati

Aptinyx Clinical Site, Ann Arbor